Inside IPEC: IPEC–Americas Releases Good Distribution Practices Audit Guide - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside IPEC: IPEC–Americas Releases Good Distribution Practices Audit Guide
A new audit guide aims to improve supply-chain security and supplier qualification practice.

Pharmaceutical Technology
Volume 35, Issue 3, pp. 132-133

Early in January 2011, the International Pharmaceutical Excipients Council of the Americas (IPEC–Americas) updated its 2000 GMP Audit Guideline for Distributors of Bulk Pharmaceutical Excipients and renamed it the IPEC–Americas Good Distribution Practices Audit Guide for North American Distribution of Pharmaceutical Excipients. Although the new good distribution practice (GDP) audit guide is meant for distributors, brokers, and traders of excipients in North America primarily, it also can be a resource for the audit of distributors worldwide. For the purposes of this article, distributor is defined as encompassing the following: distributors who take possession of an excipient and may conduct a range of activities from repackaging and storage through warehousing and shipping; brokers who arrange for a transaction between an excipient manufacturer and an excipient user but never take physical possession of the excipient; and traders who contract with the excipient user before finding a source of the excipient for the pharmaceutical manufacturer and also never takes physical possession of the excipient.

Growing security concerns

Expectations for auditing excipient distributors have grown significantly in recent years. In June 2009, FDA held a conference on economically motivated adulteration (EMA). FDA's working definition of EMA is "the fraudulent, intentional substitution or addition of a substance in a product for the purpose of increasing the apparent value of the product or reducing the cost of its production (i.e., for economic gain)." EMA is a concern for excipients, in particular, because their supply chain from the manufacturer to end-user frequently involves multiple distributors and, thus, weakens their supply-chain security. FDA investigators also have recently been inspecting supplier-qualification programs at pharmaceutical manufacturers with the expectation that drug manufacturers qualify their distributors and the excipient manufacturers they represent. Industry expressed great interest in the qualification of distributors at two recent conferences, IVT's November 2010 Life Sciences Forum Supplier Audits and the American Society for Quality's January 2010 Northeast Pharmaceutical GMP/Quality Conference. Attendees discussed how certain audit tools could help assess distributors and their excipient suppliers.

The IPEC–Americas audit guide supports the IPEC GDP Guide for Pharmaceutical Excipients issued in 2006. The audit guide provides open-ended questions that are meant to help the auditor begin a dialogue with the distributor and thereby enable the auditor to obtain objective evidence from which to establish conformance of the distributor to applicable provisions of the GDP guide. The audit guide also provides information on how to develop an excipient distributor certification program (see section below).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here